サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1660555

心臓バイオマーカーの世界市場：市場規模、シェア、予測、動向分析：タイプ別、用途別、エンドユーザー別、地域別-2031年までの予測

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031

出版日
ページ情報
英文 165 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
心臓バイオマーカーの世界市場：市場規模、シェア、予測、動向分析：タイプ別、用途別、エンドユーザー別、地域別-2031年までの予測
出版日: 2025年01月21日
発行: Meticulous Research
ページ情報: 英文 165 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心臓バイオマーカーの市場規模は、2023年に51億5,000万米ドルと評価されました。この市場は、2024年の55億7,000万米ドルから2031年には100億8,000万米ドルに達すると予測され、2024年から2031年の予測期間中のCAGRは8.8%になると見込まれています。

心臓バイオマーカー市場の成長は、心血管疾患の有病率の上昇加、高齢者人口の増加、心臓バイオマーカーの技術進歩、ヘルスケア支出の増加、心血管疾患啓発プログラムの増加によって牽引されます。しかし、バイオマーカーの特異性と感度が限定的であること、バイオマーカー検査のコストが高いことが、この市場の成長を抑制しています。

さらに、新規バイオマーカー検査の導入や、ポイントオブケア検査へのバイオマーカーの統合は、市場成長の機会を生み出すと期待されています。しかし、代替診断技術が利用可能であることは、世界の心臓バイオマーカー市場における大きな課題です。

タイプ別では、トロポニンセグメントが予測期間中に最大のシェアを占めました。このセグメントのシェアが大きいのは、心血管疾患の診断における高い特異性と感度、心血管疾患の負担増、診断技術の進歩が市場を牽引しているためと考えられます。例えば、2024年10月、Siemens Healthineers AG（ドイツ）は、心臓発作を予測するためのAtellica IM高感度トロポニンI（TnIH）検査の新しい進歩的な主張のFDAの承認を受けました。

用途別では、2024年の予測期間中、心筋梗塞セグメントが最大のシェアを占めました。同分野のシェアが大きいのは、疾病負担の急増と死亡率の上昇、早期診断に対する意識の高まり、ポイントオブケア検査の進歩、心筋梗塞のリスクが高く心臓バイオマーカーを必要とする高齢者人口の急増などが背景にあります。

エンドユーザー別では、2024年の予測期間中に最大のシェアを占めたのはラボ検査セグメントでした。このセグメントのシェアが大きいのは、診断ラボの数の増加、疾患の早期診断に対する意識の高まり、熟練した専門家の利用可能性、ヘルスケアインフラ開発への投資の増加によるものです。

当レポートでは、世界の心臓バイオマーカー市場について調査し、市場の現状とともに、タイプ別、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場の定義と範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の成長に影響を与える要因

  • 概要
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
  • 動向
  • 規制分析
  • ポーターのファイブフォース分析

第5章 心臓バイオマーカー市場の評価、タイプ別

  • 概要
  • トロポニン
  • クレアチンキナーゼMb（Ck-Mb）
  • ミオグロビン
  • B型ナトリウム利尿ペプチド（Bnp）
  • N末端プロB型ナトリウム利尿ペプチド（Nt-Probnp）
  • その他のタイプ

第6章 心臓バイオマーカー市場の評価、用途別

  • 概要
  • 心筋梗塞
  • 急性冠症候群
  • うっ血性心不全
  • その他

第7章 心臓バイオマーカー市場の評価、エンドユーザー別

  • 概要
  • 臨床検査
  • ポイントオブケア検査

第8章 心臓バイオマーカー市場の評価、地域別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • スイス
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合分析

  • 概要
  • 主な成長戦略
  • 競合ベンチマーキング
  • 競合ダッシュボード
  • 市場シェア/ランキング分析、主要企業別、2023年

第10章 企業プロファイル（事業概要、財務概要、製品ポートフォリオ、戦略開発、SWOT分析）

  • F. Hoffman-La-Roche Ltd
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineer AG
  • Danaher Corporation
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Life Diagnostics, Inc.
  • Creative Diagnostics
  • Randox Laboratories Ltd
  • QuidelOrtho Corporation

第11章 付録

図表

LIST OF TABLES

  • Table 1. Key Government Regulatory Agencies
  • Table 2. Cardiac Biomarker Types: Advantages & Disadvantages
  • Table 3. Global Cardiac Biomarkers Market Size, By Type, 2022-2031 (USD Million)
  • Table 4. Global Troponin Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 5. Global Creatine Kinase Mb (Ck-Mb) Biomarkers Market, By Country/ Region, 2022-2031 (USD Million)
  • Table 6. Global Myoglobin Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 7. Global BNP Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 8. Difference Between BNP and NT-proBNP
  • Table 9. Global NT-proBNP Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 10. Global Other Biomarker Types Market, By Country/Region, 2022-2031 (USD Million)
  • Table 11. Global Cardiac Biomarkers Market Size, By Application, 2022-2031 (USD Million)
  • Table 12. Global Cardiac Biomarkers Market for Myocardial Infarction, By Country/Region, 2022-2031 (USD Million)
  • Table 13. Global Cardiac Biomarkers Market for Acute Coronary Syndrome, By Country/Region, 2022-2031 (USD Million)
  • Table 14. Global Cardiac Biomarkers Market for Congestive Heart Failure, By Country/Region, 2022-2031 (USD Million)
  • Table 15. Global Cardiac Biomarkers Market for Other Application, By Country/Region, 2022-2031 (USD Million)
  • Table 16. Global Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 17. Global Cardiac Biomarkers Market for Laboratory Testing, By Country/Region, 2021-2031 (USD Million)
  • Table 18. Global Cardiac Biomarkers Market for Point-of-Care Testing, By Country/Region, 2021-2031 (USD Million)
  • Table 19. Global Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 20. North America: Cardiac Biomarkers Market, By Country, 2022-2031 (USD Million)
  • Table 21. North America: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 22. North America: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 23. North America: Cardiac Biomarkers Market, By End Use, 2022-2031 (USD Million)
  • Table 24. U.S.: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 25. U.S.: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 26. U.S.: Cardiac Biomarkers Market, By End Use, 2022-2031 (USD Million)
  • Table 27. Canada: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 28. Canada: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 29. Canada: Cardiac Biomarkers Market, By End Use, 2022-2031 (USD Million)
  • Table 30. Europe: Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 31. Europe: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 32. Europe: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 33. Europe: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 34. Germany: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 35. Germany: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 36. Germany: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 37. France: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 38. France: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 39. France: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 40. U.K.: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 41. U.K.: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 42. U.K.: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 43. Italy: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 44. Italy: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 45. Italy: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 46. Spain: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 47. Spain: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 48. Spain: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 49. Switzerland: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 50. Switzerland: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million
  • Table 51. Switzerland: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 52. Rest of Europe: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 53. Rest of Europe: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 54. Rest of Europe: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 55. Asia-Pacific: Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 56. Asia-Pacific: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 57. Asia-Pacific: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 58. Asia-Pacific: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 59. Japan: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 60. Japan: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 61. Japan: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 62. China: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 63. China: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 64. China: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 65. India: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 66. India: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 67. India: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 68. Australia: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 69. Australia: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 70. Australia: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 71. Rest of Asia Pacific: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 72. Rest of Asia Pacific: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 73. Rest of Asia Pacific: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 74. Latin America: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 75. Latin America: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 76. Latin America: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 77. Middle East & Africa: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 78. Middle East & Africa: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 79. Middle East & Africa: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 80. Recent Developments, By Company, 2021-2024

LIST OF FIGURES

  • Figure 1. Market Ecosystem
  • Figure 2. Secondary Sources referenced for this study
  • Figure 3. Primary Research Techniques
  • Figure 4. Key Executives Interviewed
  • Figure 5. Breakdown of Primary Interviews (Supply Side & Demand Side)
  • Figure 6. Market Sizing & Growth Forecast Approach
  • Figure 7. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
  • Figure 8. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
  • Figure 9. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
  • Figure 10. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
  • Figure 11. Impact Analysis of Market Dynamics
  • Figure 12. USFDA regulatory pathways for cardiac biomarkers
  • Figure 13. EU regulatry pathway - IVDR 2017/746
  • Figure 14. China: medical device classification and premarket requirements for crdaiac biomarkers products
  • Figure 15. Porter's Five Forces Analysis: cardiac biomarkers market
  • Figure 16. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
  • Figure 17. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
  • Figure 18. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
  • Figure 19. Global pharmaceutical R&D spending, 2012-2026 (USD Billion)
  • Figure 20. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
  • Figure 21. North America: Cardiac biomarkers Market Snapshot
  • Figure 22. U.S. population aged 65 years and above, 2022-2026 (million)
  • Figure 23. U.S.: cardiovascular diseases prevalence rate in the population, 2021-2035
  • Figure 24. Europe: Cardiac biomarkers Market Snapshot
  • Figure 25. Asia Pacific: Cardiac biomarkers Market Snapshot
  • Figure 26. Latin America: Cardiac biomarkers Market Snapshot
  • Figure 27. Middle East & Africa: Cardiac biomarkers Market Snapshot
  • Figure 28. Key Growth Strategies Adopted By Leading Players, 2021-2024
  • Figure 29. Cardiac biomarkers Market: Competitive Benchmarking, By Type
  • Figure 30. Cardiac biomarkers Market: Competitive Benchmarking, By Region
  • Figure 31. Cardiac biomarkers Market: Competitive Dashboard
  • Figure 32. Cardiac biomarkers Market: Market Share Analysis, By Key Players (2023)
  • Figure 33. F. Hoffman-La-Roche Ltd: Financial Snapshot (2023)
  • Figure 34. Bio-Rad Laboratories, Inc.: Financial SNAPSHOT (2023)
  • Figure 35. Abbott Laboratories: Financial Snapshot (2023)
  • Figure 36. Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
  • Figure 37. Siemens Healthineer AG: Financial Snapshot (2024)
  • Figure 38. Danaher Corporation: Financial Snapshot (2023)
  • Figure 39. bioMerieux SA: Financial Snapshot (2023)

FIGURE 40. Becton, Dickinson and Company: FINANCIAL SNAPSHOT (2024)

  • Figure 41. QuidelOrtho Corporation: FINANCIAL SNAPSHOT (2023)
目次
Product Code: MRHC - 1041448

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing)- Global Forecast to 2031

The cardiac biomarkers market was valued at $5.15 billion in 2023. This market is expected to reach $10.08 billion by 2031 from an estimated $5.57 billion in 2024, at a CAGR of 8.8% during the forecast period of 2024-2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the cardiac biomarkers market is driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in cardiac biomarkers, increasing healthcare expenditure, and increasing cardiovascular disease awareness programs. However, limited specificity and sensitivity of biomarkers and high cost of biomarker testing restrain the growth of this market.

Furthermore, the introduction of novel biomarkers tests and integration of biomarkers in point-of-care testing are expected to generate market growth opportunities. However, the availability of alternative diagnostic technologies are major challenges in the global cardiac biomarkers market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over years (2021-2024). The key players operating in the cardiac biomarkers market are Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), BioMerieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc. (U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.).

Among all the type studied in this report, the troponin segment accounted for the largest share during the forecast period. The segment's larger share can be attributed to its high specificity and sensitivity in diagnosing cardiovascular diseases, increasing burden of cardiovascular diseases and advancements in diagnostic technologies drives the market. growing number of product approvals and availability of troponin testing. For instance, in October 2024, Siemens Healthineers AG (Germany) received FDA approval of a new progressive claim for Atellica IM high-sensitivity troponin I (TnIH) test for predicting Heart Attack.

Among all the applications studied in this report, in 2024, myocardial infarction segment accounted for the largest share during the forecast period. The segment's larger share can be attributed to the growing burden of diseases rapidly and mortality rate, increasing awareness about early diagnosis, advancements in point-of-care testing and rapidly growing geriatric population with high risk of myocardial infarction that demands for cardiac biomarkers.

Among all the end user studied in this report, in 2024, laboratory testing segment accounted for the largest share during the forecast period. The segment's larger share can be attributed to the rising number of diagnostics laboratories, increasing awareness about early disease diagnosis, availability of skilled professionals, and increasing investments in developing healthcare infrastructure. laboratory testing can provide high throughput screening capacity for the samples which makes them more efficient for diagnosis procedure.

An in-depth analysis of the geographical scenario of the global cardiac biomarkers market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia Pacific is projected to register the highest CAGR during the forecast period. The fastest growth of the market is due to the rising number of cardiovascular diseases, robust healthcare infrastructure, widespread adoption of cardiac biomarkers as a diagnostic and prognostic tool for diseases are further expected to drive the cardiac biomarkers market in the region.

Scope of the Report:

Cardiac biomarkers Market Assessment-by Type

  • Troponin
  • Creatine kinase MB (CK-MB)
  • Myoglobin
  • B-Type Natriuretic Peptide (BNP)
  • N-terminal pro B-type natriuretic peptide (NT-proBNP)
  • Other Types ()

(Note: other types include Galectin, Homocysteine, C-Reactive Protein, and D-dimer)

Cardiac biomarkers Market Assessment-by Application

  • Myocardial Infarction
  • Congestive heart failure
  • Acute Coronary Syndrome
  • Other Applications

(Note: Other applications include Atherosclerosis, Pulmonary Embolism, and Atrial Fibrillation)

Cardiac biomarkers Market Assessment-by End User

  • Laboratory Testing
  • Point-of-care Testing

Cardiac biomarkers Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • Switzerland
    • Netherlands
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Market Definition & Scope

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for The Study

3. Executive Summary

4. Factors Affecting Market Growth

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. Increasing Prevalence of Cardiovascular Diseases and Rising Geriatric Population
    • 4.2.2. Technological Advancements in Cardiac Biomarkers
    • 4.2.3. Increasing Healthcare Expenditure
    • 4.2.4. Inreasing Cardiovascular Disease Awareness Programs
  • 4.3. Restraints
    • 4.3.1. Limited Specificity and Sensitivity of Biomarkers
    • 4.3.2. High Cost of Biomarker Testing
  • 4.4. Opportunity
    • 4.4.1. Introduction of Novel Biomarker Tests
    • 4.4.2. Integration of Biomarkers in Point-of-Care Testing
  • 4.5. Challenges
    • 4.5.1. Alternative Diagnostic Technologies
  • 4.6. Trends
    • 4.6.1. Focus on Multi-Analyte Panels
  • 4.7. Regulatory Analysis
  • 4.8. Porter's Five Forces Analysis

5. Cardiac Biomarkers Market Assessment-By Type

  • 5.1. Overview
  • 5.2. Troponin
  • 5.3. Creatine Kinase Mb (Ck-Mb)
  • 5.4. Myoglobin
  • 5.5. B-Type Natriuretic Peptide (Bnp)
  • 5.6. N-Terminal Pro-B-Type Natriuretic Peptide (Nt-Probnp)
  • 5.7. Other Types

6. Cardiac Biomarkers Market Assessment-By Application

  • 6.1. Overview
  • 6.2. Myocardial Infarction
  • 6.3. Acute Coronary Syndrome
  • 6.4. Congestive Heart Failure
  • 6.5. Other Applications

7. Cardiac Biomarkers Market Assessment-By End User

  • 7.1. Overview
  • 7.2. Laboratory Testing
  • 7.3. Point-of-Care Testing

8. Cardiac Biomarkers Market Assessment-By Geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. Uk
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Switzerland
    • 8.3.7. Rest of Europe (Roe)
  • 8.4. Asia-Pacific
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Rest of Asia-Pacific (Roapac)
  • 8.5. Latin America
  • 8.6. Middle East & Africa

9. Competition Analysis

  • 9.1. Overview
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Benchmarking
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share/Ranking Analysis, By Key Players, 2023

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and Swot Analysis*)

  • 10.1. F. Hoffman-La-Roche Ltd (Switzerland)
  • 10.2. Bio-Rad Laboratories, Inc. (U.S.)
  • 10.3. Abbott Laboratories (U.S.)
  • 10.4. Thermo Fisher Scientific Inc. (U.S.)
  • 10.5. Siemens Healthineer AG (Germany)
  • 10.6. Danaher Corporation (U.S.)
  • 10.7. bioMerieux SA (France)
  • 10.8. Becton, Dickinson and Company (U.S.)
  • 10.9. Life Diagnostics, Inc. (U.S.)
  • 10.10. Creative Diagnostics (U.S.)
  • 10.11. Randox Laboratories Ltd (U.K.)
  • 10.12. QuidelOrtho Corporation (U.S.)

(Note: Swot Analysis* Will Be Provided of The Top 5 Companies)

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports